Mavorixafor
Xolremdi (mavorixafor) is a small molecule pharmaceutical. Mavorixafor was first approved as Xolremdi on 2024-04-26. The pharmaceutical is active against C-X-C chemokine receptor type 4.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| xolremdi | New Drug Application | 2024-06-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| infections | EFO_0000544 | D007239 | — |
| warts | — | D014860 | B07 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
13 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neutropenia | D009503 | — | D70 | 1 | 1 | 1 | — | — | 2 |
| Syndrome | D013577 | — | — | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 1 | — | — | — | 3 |
| Renal cell carcinoma | D002292 | EFO_0000376 | — | 2 | 2 | — | — | — | 2 |
| Carcinoma | D002277 | — | C80.0 | 2 | 2 | — | — | — | 2 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 1 | — | — | — | 1 |
| Triple negative breast neoplasms | D064726 | — | — | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 1 | — | — | — | — | 1 |
| Waldenstrom macroglobulinemia | D008258 | HP_0005508 | C88.0 | 1 | — | — | — | — | 1 |
| Healthy volunteers/patients | — | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mavorixafor |
| INN | mavorixafor |
| Description | AMD 070 is an aminoquinoline. |
| Classification | Small molecule |
| Drug class | CXCR receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NCCCCN(Cc1nc2ccccc2[nH]1)[C@H]1CCCc2cccnc21 |
Identifiers
| PDB | — |
| CAS-ID | 558441-90-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL518924 |
| ChEBI ID | — |
| PubChem CID | 11256587 |
| DrugBank | DB05501 |
| UNII ID | 0G9LGB5O2W (ChemIDplus, GSRS) |
Target
Agency Approved
CXCR4
CXCR4
Organism
Homo sapiens
Gene name
CXCR4
Gene synonyms
NCBI Gene ID
Protein name
C-X-C chemokine receptor type 4
Protein synonyms
CD184, CD184 antigen, chemokine (C-X-C motif) receptor 4, FB22, Fusin, HM89, LAP-3, LCR1, LESTR, Leukocyte-derived seven transmembrane domain receptor, Lipopolysaccharide-associated protein 3, LPS-associated protein 3, neuropeptide Y receptor Y3, neuropeptide Y3 receptor, NPYRL, SDF-1 receptor, seven transmembrane helix receptor, seven-transmembrane-segment receptor, spleen, Stromal cell-derived factor 1 receptor
Uniprot ID
Mouse ortholog
Cxcr4 (12767)
C-X-C chemokine receptor type 4 (Q4KMW1)
Alternate
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 284 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
10 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use